Company Profile
Organogenesis Stock Price, News & Analysis
Company overview
Business overview
Organogenesis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Organogenesis is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Organogenesis follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Organogenesis sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ORGO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Organogenesis’s catalysts are PuraPly, Affinity, and the broader wound-care and surgical portfolio. The business moves on adoption, reimbursement, and product-mix execution.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Source: Organogenesis
- 02
- 03
Organogenesis Applauds CMS’s Significant Step In Payment Reform
Source: Organogenesis
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.